In case of a pregnancy in a patient infected with hepatitis B virus there is a risk of intrauterine fetus infection, which rises significantly with the serological profile of positive hepatitis B surface antigen, hepatitis Be antigen and in the presence of HBV DNA in serum. Therefore, in clinical practice the monitoring of antiviral therapy in chronic hepatitis B in women of reproductive age is becoming especially important. The safety of lamivudine use in pregnant women infected with hepatitis B virus has not yet been proven. In this case, the patient became pregnant during the treatment with lamivudine and when hepatitis B virus replication markers were present in the serum (hepatitis B surface antigen, hepatitis Be antigen, hepatitis B virus DNA). Treatment with lamivudine lasted through the first 6 weeks of pregnancy, which was complicated by a possibility of intrauterine hepatitis B virus infection, did not cause any fetus injury.
Download full-text PDF |
Source |
---|
Rev Gastroenterol Peru
January 2025
Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Gastroenterología, Hospital Sótero del Río, Santiago, Chile.
Introduction: Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections are a global public health concern. In 2019, there were 295.9 million people with chronic hepatitis B and 57.
View Article and Find Full Text PDFIntroduction: 58 million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antivirals are highly effective; however, they are burdened by high costs and the unchanged risk of HCC and reinfection, making prophylactic countermeasures an urgent medical need. HCV high genetic diversity is one of the main obstacles to vaccine development.
View Article and Find Full Text PDFAnal Methods
November 2017
Institute of Biomedical Chemistry, ul. Pogodinskaya, 10, Moscow, Russia.
A combined AFM/MS method was employed for protein registration in solution. This method is based on reversible specific capturing of a target protein from a large volume of analyzed solution onto a small sensor area of a chip with immobilized aptamer ligands. Fishing of the core antigen of hepatitis C virus (HCVcoreAg) from 10 M solution of this protein in buffer was carried out.
View Article and Find Full Text PDFIntern Med J
January 2025
Department of Infectious Diseases, Westmead Hospital, Sydney, New South Wales, Australia.
Background: With improved outcomes in human immunodeficiency virus (HIV) due to the use of anti-retroviral therapy, ensuring adequate preventative healthcare and management of HIV-related comorbidities is essential.
Aims: To evaluate adherence with recommended guidelines for comorbidity and immunisation status screening amongst people living with HIV within a hospital-based setting across two timepoints.
Methods: A single-centre retrospective case series was conducted at a hospital between 2011 and 2021.
Toxicology
January 2025
Department of Pharmacology, Shantou University Medical College, Shantou 515041, China. Electronic address:
Aflatoxin B1 (AFB1) has been reported to synergize with hepatitis B virus (HBV) to induce development of hepatocellular carcinoma (HCC). Precise daily exposure to AFB1 and its contribution to liver injury have not been quantified and have even been disregarded due to lack of convenient detection, and the strong species specificity of HBV infection has restricted research on their synergistic harm. Hence, our objective was to investigate the molecular mechanisms by which AFB1 exacerbates HBV-related injury.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!